Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul L. Berns
AddedMar 31, 2024
UpdatedMay 31, 2026
Paul L. Berns

Paul L. Berns

Board Member, Unity Biotechnology

Crunchbase

Paul L. Berns's Career

Unity Biotechnology
Unity Biotechnology

South San Francisco, CA, US

Board Member· Board
Epirium Bio
Epirium Bio

San Diego, CA, US

Board Member· Board
BlackThorn Therapeutics
BlackThorn Therapeutics

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul L. Berns's Career

Unity Biotechnology
Unity Biotechnology
Public$294.9M702009South San Francisco, CA, US
Board Member· Board

Leadership at Unity Biotechnology

Cami SamuelsCami SamuelsBoard Member
Anirvan GhoshAnirvan GhoshBoard Member
Michael SamarMichael SamarBoard Member
Nathaniel DavidNathaniel DavidBoard Member
Keith LeonardKeith LeonardBoard Member
James P. LovelyJames P. LovelyBoard Member

Similar to Unity Biotechnology

United TherapeuticsUnited TherapeuticsSilver Spring, MD, USPharmaceuticalsest. 1996United TherapeuticsSilver Spring, MD, US · est. 1996

United Therapeutics, a Maryland-based biotech firm, develops pharmaceuticals for vascular diseases using synthetic prostacyclin.

Public985
Retro BiosciencesRetro BiosciencesSan Francisco, CA, USTherapeuticsest. 2021Retro BiosciencesSan Francisco, CA, US · est. 2021

Retro Biosciences, an American medical firm, pioneers in cellular reprogramming and plasma-inspired therapeutics.

Late Stage Private · $180M44
AgeX TherapeuticsAgeX TherapeuticsAlameda, CA, USBiotechest. 2017AgeX TherapeuticsAlameda, CA, US · est. 2017

AgeX Therapeutics, a US biotech firm, innovates in cell immortality and regenerative biology to treat aging and related diseases.

Public · $99.8M5
Epirium Bio
Epirium Bio
Series A$86.4M302008San Diego, CA, US
Board Member· Board

Leadership at Epirium Bio

Alan MaiselAlan MaiselFounder
Josh RichardsonJosh RichardsonBoard Member
Patrick EnrightPatrick EnrightBoard Member
Russell J. CoxRussell J. CoxCEO
Sandy MahatmeSandy MahatmeBoard Member

Similar to Epirium Bio

Epic-BioEpic-BioSouth San Francisco, CA, USGene Therapiesest. 2018Epic-BioSouth San Francisco, CA, US · est. 2018

Epic Bio: Pioneering the new era of gene expression modulation.

Series A · $55M35
Epirus BiopharmaceuticalsEpirus BiopharmaceuticalsBoston, MA, USPharmaceuticals, Therapeuticsest. 2000Epirus BiopharmaceuticalsBoston, MA, US · est. 2000

Boston-based EPIRUS Biopharmaceuticals develops novel treatments for hypothyroidism and immuno-inflammatory diseases globally.

Public · $83.1M73
EpiBiologicsEpiBiologicsSan Mateo, CA, USTargeted Therapiesest. 2022EpiBiologicsSan Mateo, CA, US · est. 2022

EpiBiologics: Pioneering antibody-based therapies targeting disease-driving proteins.

Series A · $73M38
Petri BioPetri BioLos Angeles, CA, USTherapeuticsest. 2019Petri BioLos Angeles, CA, US · est. 2019

Petri Bio: A biotech firm innovating gut microbe-based therapeutics.

Seed · $255k3
BlackThorn Therapeutics
BlackThorn Therapeutics
Acquired$138M02015San Francisco, CA, US
Board Member· Board

Leadership at BlackThorn Therapeutics

George GolumbeskiGeorge GolumbeskiBoard Member
Mark H N CorriganMark H N CorriganBoard Member
Alex TkachenkoAlex TkachenkoFounder
Julie SunderlandJulie SunderlandBoard Member
Lori HuLori HuBoard Member
Kristina BurowKristina BurowBoard Member

Paul L. Berns's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Paul L. Berns

Carol SuhCarol SuhBoard Member · HI-BioMike PooleMike PooleBoard Member · CerevanceDennis KnockeDennis KnockeBoard Member · Nerium BiotechnologyRobert GoldbergRobert GoldbergCo-Founder · NeumitraTim KutzkeyTim KutzkeyBoard Member · SurrozenJosh DisbrowJosh DisbrowBoard Member · Ampio Pharmaceuticals